GTHX - G1 Therapeutics Inc
IEX Last Trade
7.11
0 0%
Share volume: 1,146,615
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.11
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
3%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.14%
1 Month
78.20%
3 Months
114.80%
6 Months
113.51%
1 Year
308.62%
2 Year
-48.85%
Key data
Stock price
$7.11
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.08 - $7.19
52 WEEK CHANGE
$3.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Mark Velleca
Region: US
Website: http://www.g1therapeutics.com/
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.g1therapeutics.com/
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
Recent news